Device Trial Radar · NCT06228274
Assessment of Safety and Efficacy of ARTHRUM 2.5% for Treatment of Painful Osteoarthritis of the Knee
Last checked: Nov 20, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Mar 2013
Primary completion
Sep 2015
Study completion Mar 2017
Sponsor
- Lead sponsor
- LCA PharmaceuticalNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- BIOSTATEM
- First posted
- Jan 29, 2024
Design
- Study type
- Observational
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ARTHRUM 2.5% MONO-INJECTION as symptomatic treatment by joint injection extends the conservative therapeutic arsenal in Knee osteoarthritis. The reduction of functional limits and disabilities induced by knee osteoarthritis as well as improvement of quality of life of patients is a public health need registered amongst the priorities established by the French law of 9 August 2004 relative to Public Health policy. However, the response to this need is not limited to treatment with health products. This prospective, open, multi-centre trial of the real-life efficacy of ARTHRUM 2.5% aims to demonstrate the efficacy of a single joint injection of this treatment on pain, during 6 months, in the symptomatic treatment of patients suffering from Knee osteoarthritis
Conditions
- Knee Osteoarthritis
Interventions
ARTHRUM 2.5%Device
ARTHRUM 2.5%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of ARTHRUM 2.5% single joint injection on pain assessed by Likert scale on five levelsTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.